c-Abl, the non-receptor tyrosine kinase is associated with EP, a DNA element found in promoters/enhancers of dierent viruses and cell-cycle regulated genes. EP-DNA binds RFXI, a member of a novel family of DNA-binding proteins that is conserved through evolution and in yeast, it controls dierentiation and exit from the mitotic cycle to G 0 . EP-associated proteins are preferentially tyrosine phosphorylated and the associated c-Abl has strong tyrosine kinase activity. Here we investigated the molecular mechanism underlying this c-Abl kinase activity. We show that RFXI and c-Abl are in direct interaction, in vitro and in cell extracts, through the RFXI proline rich (PxxP) motif and the c-Abl SH3 domain. Remarkably, this interaction signi®cantly potentiates cAbl but not v-Abl auto-kinase activity. Collectively, we describe a novel mechanism of c-Abl recruitment to a de®ned DNA-cis element with its concomitant kinase activation. We propose that this mechanism may act to regulate cell-cycle control genes.
Introduction
The product of the c-abl proto-oncogene is a ubiquitously expressed 140 kDa non-receptor tyrosine kinase that is localized predominantly to the nucleus (Van Etten et al., 1989; Wang, 1994) . c-Abl is subdivided into four regions: two N-terminal regulatory domains termed Src homology (SH) 2 and 3, a tyrosine kinase domain and a unique C-terminal tail (Ramakrishnan and Rosenberg, 1989; Wang, 1993 Wang, , 1994 . The SH2 and SH3 domains are known to mediate protein-protein interactions with speci®c tyrosine phosphorylated sequences and proline-rich motifs, respectively (Cicchetti et al., 1992; Ren et al., 1993; Cohen et al., 1995; Pawson, 1995a,b) . The long C-terminal tail contains an actin binding domain (McWhirter and Wang, 1993; Van Etten et al., 1994) and several PxxP motifs capable of interacting with Crk1, Abi1 and Abi2 proteins (Ren et al., 1994; Feller et al., 1994a,b; Shi et al., 1995; Dai and Pendergast, 1995) . Also, this region has a DNA binding activity Wang, 1990, 1992) with three high mobility group-like domains (Miao and Wang, 1996) . Genetically, the C-terminus is crucial for c-Abl function, as mice homozygous to a C-terminally truncated c-Abl (deleted at the DNA binding domain) exhibit neonatal lethality to the same degree as null mice do (Tybulewicz et al., 1991; Schwartzberg et al., 1991) .
In cells, the kinase activity of c-Abl is highly regulated and hardly detectable but can be detected in proliferating cells (Konopka and Witte, 1985; Jackson and Baltimore, 1989; Pendergast et al., 1991a; Liu et al., 1996; Lewis et al., 1996) . c-Abl overexpression inhibits cell growth and its kinase activity is required for a G 1 arrest in response to treatment with DNA damaging agents (Van Etten et al., 1989; Sawyers et al., 1994; Kharbanda et al., 1995) . In sharp contrast, overexpression of constitutively active Abl mutants leads to growth stimulation and a change in cell shape and behavior (reviewed in Wang, 1993) . Deleting, mutating or swapping the c-Abl SH3 domain was sucient to render it constitutively active, cytoplasmic and transforming (Van Etten et al., 1989; Mayer and Baltimore, 1994) . Therefore, it has been suggested that SH3 association with cellular factors negatively regulates cAbl activity (Konopka and Witte, 1985; Pendergast et al., 1991b; Mayer and Baltimore, 1994) . Indeed, two proteins Abi1 and Abi2 were recently identi®ed as modulators of c-Abl transforming activity (Dai and Pendergast, 1995; Shi et al., 1995) . Each of these proteins interacts simultaneously with the SH3 domain and a proline-rich motif at the C-terminal tail of c-Abl. Presumably, this interaction might sterically sequester cAbl kinase domain.
We have previously demonstrated the association of c-Abl with a speci®c DNA element termed EP (Dikstein et al., 1992) . EP is a key functional element of the hepatitis B virus (HBV) enhancer (Ostapchuk et al., 1989; Zhang et al., 1990a Zhang et al., ,b, 1991 Dikstein et al., 1990) . A second component of the EP nucleo-protein complex is RFX1. RFX1, a 140 kDa protein, belongs to a family of DNA binding proteins conserved in evolution down to yeast (Reith et al., 1990 (Reith et al., , 1994 Steimle et al., 1995; Wu and McLeod, 1995; Emery et al., 1996) . RFX1 binds the EP site and activates the HBV enhancer (Siegrist et al., 1993) . However, when examined in isolation, not in the context of the enhancer, RFX1 was found to have multiple functional domains (Katan et al., 1997) . It has a transcriptional repression domain which overlaps with the dimerization domain, and an activation domain at its central region. These domains neutralize each other giving rise to mostly transcriptionally inactive protein.
Most intriguing, RFX1 contains a modulator region which overlaps with the proline rich region at its Nterminus that aects its level of expression and DNA binding activity.
Based on in vivo labeling and protein puri®cation assays, it has been found that the components of the EP nucleo-protein complex are tyrosine phosphorylated (Dikstein et al., 1996) . Here, we investigated the mechanism underlying c-Abl kinase activation. We report that both EP-DNA associated proteins; RFX1 and c-Abl, are in direct interaction in nuclear extracts. Moreover, in vitro, RFX1 activates c-Abl auto-kinase activity. This activation is mediated through a speci®c association of the RFX1-PxxP motif with the c-Abl-SH3 domain, the same domains which are required for RFX1-c-Abl interaction in vivo. In agreement with these results we observed that in vivo the EP-DNA associated c-Abl protein but not RFX1 is highly phosphorylated at tyrosine residues. As the yeast homolog of RFX1 regulates cell fate, our observations may provide a molecular mechanism for the mode of action of c-Abl in cell growth.
Results

Recombinant RFX1 potentiates c-Abl kinase activity
The EP nucleo-protein complex contains at least two protein components, c-Abl and RFX1 (Dikstein et al., 1992; Siegrist et al., 1993) . The EP associated c-Abl has a strong kinase activity (Dikstein et al., 1996) . We therefore checked the possibility that RFX1 might directly regulate the c-Abl kinase activity. This possibility was addressed here in vitro by employing bacterial recombinant c-Abl (rc-Abl) and RFX1 (rRFX1) proteins. In a kinase reaction, rc-Abl alone was poorly phosphorylated (Figure 1a , lane 1) whereas rRFX1 alone was inactive (lane 2). However, when the two proteins were mixed we observed an increase in phosphorylation (lane 3). Two phosphorylated bands appeared around 140 kDa. Although not directly determined one could be phosphorylated RFX1 and the other phosphorylated c-Abl. The eect of rRFX1 was speci®c as mixing a similar amount of a control recombinant protein had no eect on the phosphorylation pattern when either added alone to c-Abl (lane 4) or in combination with rRFX1 (lane 5). Moreover, a 2D-phosphoamino acid analysis con®ned that the proteins were phosphorylated only at tyrosine residues (Figure 1b) , indicating that c-Abl was the sole kinase in the reactions.
In order to examine whether the increase in phosphorylation is the result of RFX1 phosphorylation or the result of an increase in the c-Abl autokinase activity, we used for the following experiments a truncated c-Abl protein (amino acids 15 ± 667). This protein contains the SH3, SH2 and kinase domains together with a part of the C-terminal tail but lacks the DNA and actin binding domains. When puri®ed from bacteria, through a six-histidine tag at its N-terminus, in addition to the expected 90 kDa protein a 65 kDa truncated c-Abl protein was also obtained (see for example Figure 7b ). Using this protein we observed an RFX1-dependent potentiation of c-Abl auto-phosphorylation ( Figure 2a , lanes 1 and 2) whereas rRFX1 phosphorylation was inecient. The potentiation of cAbl kinase activity is rRFX1 dependent and not seen with rc-Abl(15 ± 667) alone (lane 1) or in mixture with a control protein (lane 3), as was observed with the full-length rc-Abl (Figure 1a) . Additionally, increasing amounts of either rRFX1 or rc-Abl proportionally raised the auto-phosphorylation rate of c-Abl (Figure  2b ), demonstrating a dose response reaction, characteristic of enzymatic activity. Most important, anti-Abl antibodies immunoprecipitated the majority of the phosphorylated proteins (Figure 2c ), con®rming c-Abl auto-phosphorylation. This activity is kinase domain dependent as a kinase mutant of Abl did not support phosphorylation. These results demonstrate the activation eect of RFX1 on the auto-phosphorylation activity of c-Abl.
Association of c-Abl with RFX1 in nuclear extracts
The DNA independent potentiation of c-Abl kinase activity of RFX1 raises the possibility that these two proteins are physically associated. This possibility was investigated by co-immunoprecipitation experiments of nuclear extracts using anti-Abl and anti-RFX1 antibodies. As expected, anti-Abl antibodies eciently and speci®cally immunoprecipitated c-Abl (Figure 3a) . Interestingly, RFX1 was co-precipitated, as revealed by incubating the same immunoblot with an anti-RFX1 antibody (Figure 3b, lane 7) . This co-immunoprecipitation is highly speci®c, as the RFX1 protein is not found in the eluates of the two control antibodies (lanes 5 and 6) and in all the wash V fractions (lanes 2 ± 4). In a reciprocal experiment, extracts were prepared from cells transfected with the HA-tagged RFX1 cDNA, immunoprecipitated with the anti-HA and control monoclonal antibodies, and analysed by Western blot. Ecient expression of HARFX1 in the transfected cells was obtained (Figure 4b , lane 6). c-Abl was coimmunoprecipitated by anti-HA and not by the control rabbit anti-mouse (RaM) antibody (Figure 4a , lanes 5 and 6). Speci®city was also apparent when the blot was The amino terminal region of RFX1 is necessary for association with c-Abl
Inspection of the RFX1 sequence revealed a proline rich amino terminal region containing ®ve PxxP repeats which are conserved between mouse and human ( Figure 5a ). PxxP motifs were shown to interact with SH3 domains (Ren et al., 1993; Cicchetti et al., 1992) . To examine the involvement of this RFX1 region in the interaction with c-Abl, nuclear extracts from cells transiently transfected with either RFX1, HARFX1, or two derivative mutants were immunoprecipitated with an anti-HA antibody (Figure 5b ). Western blot analysis with anti-RFX1 demonstrated that the dierent HA-tagged RFX1 proteins were equally expressed and precipitated by anti-HA ( Figure 5c ). Analysis of the same immunoblot with 8E9, an anti-Abl monoclonal antibody, revealed that cAbl was co-precipitated with HARFX1 and HARFX1D(77 ± 588) (lanes 2 and 4), but not with HARFX1D(1 ± 77) which lacked the PxxP motifs (lane 3). This is despite the fact that the latter was properly expressed and nuclear localized. As expected, c-Abl was not detected when cells were transfected with an RFX1 plasmid that lacked the HA-tag, ruling out cross-reaction between the anti-HA antibody and cAbl. Thus, the amino terminal region of RFX1 is necessary for the RFX1 c-Abl interaction in vivo.
The c-Abl SH3 domain speci®cally interacts with the RFX1 proline rich region
To examine whether the c-Abl-SH3 domain directly interacts with the proline rich region of RFX1, we performed a far-Western analysis. This method previously was employed to demonstrate c-Abl SH3 interaction with distinct PxxP motifs (Cicchetti et al., 1992; Ren et al., 1994) . Total extracts of bacteria that produce either RFX1, RFX1D(1 ± 77) or a control protein were separated on SDS ± PAGE and blotted. Analysis with anti-RFX1 antibody con®rmed a similar production of both recombinant RFX1 and RFX1D(1 ± 77) proteins (Figure 6a ). Also, several degradation products were observed, mainly at sizes of 52, 65, 75 and 95 kDa for RFX1 and 65 and 100 kDa for RFX1D(1 ± 77). Far-Western analysis with 32 P-labeled c-Abl-SH3 domain (amino acids 15 ± 147) showed speci®c interaction with RFX1 but not with the control proteins (Figure 6b ). The reactive bands corresponded exactly to the full length and the degradation products of rRFX1 (compare lanes 1 in Figure 6a amounts and puri®ed recombinant proteins were used. The rRFX1D(1 ± 77) protein showed no SH3 binding, whereas rRFX1D(77 ± 588), containing the PxxP region eciently bound it (Figure 6c ). Together, these data indicate that the SH3 domain of c-Abl interacts with the proline rich region of RFX1.
rRFX1 potentiates c-Abl kinase activity through direct interaction
Having demonstrated that RFX1 and c-Abl are in direct association we next asked whether this interaction is important for c-Abl tyrosine kinase activation by RFX1. It is well documented that v-Abl, lacking the SH3 domain, has a constitutive tyrosine kinase activity (Konopka and Witte, 1985; Mayer et al., 1992; Renshaw et al., 1992) . Interestingly, rRFX1 failed to potentiate v-Abl kinase activity (Figure 7a, lanes 1 ± 3) , despite the fact that v-Abl autophosphorylation level was lower than that obtained with RFX1-activated cAbl (compare lanes 2 to 8 in Figure 7a and b). Thus, strongly suggesting that the c-Abl SH3 domain interacting with RFX1 is required for c-Abl kinase activation by RFX1. rRFX1D(1 ± 77), which did not bind c-Abl (Figure 5d ), was incapable of potentiating c-Abl kinase activity (lane 10) demonstrating the requirement of the RFX1 PxxP motifs for kinase activation. Western blot analysis with an anti-Abl antibody con®rmed the presence of similar amounts of c-Abl(15 ± 667) and v-Abl in all reactions (Figure 7b ). The requirement of rRFX1 was further substantiated by the fact that anity puri®ed RFX1 antibodies essentially reduced the c-Abl kinase activity almost to the basal level (lane 9). Furthermore we have con®rmed the involvement of c-Abl kinase activity in the process by using either genistein or a kinase mutant. Genistein, a tyrosine kinase speci®c inhibitor, inhibited all phosphorylation (Figure 7a , lane 11), and no kinase activity was obtained with the kinase mutant of v-Abl (Figure 7a , lanes 4 ± 6). Collectively, these results suggest that potentiation of c-Abl auto-kinase activity by rRFX1 is highly speci®c and is regulated by direct RFX1 c-Abl interaction.
c-Abl is phosphorylated at tyrosine residues in vivo Immunoprecipitation of in vivo labeled HeLa cell extract with the 8E9 monoclonal anti-Abl antibody, brought down c-Abl containing a low level of phosphotyrosine residues (Figure 8a and d) . This antibody does not recognize the c-Abl fraction which is associated with RFX1 (8B, lane 1). The RFX1 associated c-Abl fraction is speci®cally recognized by the polyclonal 543 anti-Abl antibodies (Figure 3) . We therefore used the 8E9¯ow-through fraction, after heat treatment to seperate between RFX1 and c-Abl, to immunoprecipitate either c-Abl or RFX1 by using 543 and anti RFX1 antibodies, respectively. This c-Abl fraction, comprising only 5 ± 10% of total c-Abl (Figure 8c , compare lanes 1 and 4) is highly phosphorylated (Figure 8a , lane 4) with a high level of phospho-tyrosine (Figure 8d ). This is in full agreement with the in vitro data that suggest that RFX1 associated c-Abl is preferentially phosphorylated at tyrosine. Under these conditions RFX1 was poorly phosphorylated, mainly at serine/threonine and a very low level at tyrosine residues ( Figure 8a and lane 2d) . Speci®city of the immunoprecipitation was examined by the non relevant anti-GST antibody (Figure 8a, lane 3) . Altogether these results demonstrate that in vivo RFX1 is poorly tyrosine phosphorylated while the associated 
Discussion
Here we report the association of c-Abl with RFX1 that results in remarkable activation of the c-Abl tyrosine kinase. These observations provide a molecular explanation to the previous ®nding that the EP-DNA associated c-Abl protein has a strong kinase activity (Dikstein et al., 1996) . In cells, the kinase activity of c-Abl is tightly regulated. A major inhibitory component in c-Abl is the SH3 domain, since deleting, mutating, or swapping it results in Abl kinase activation (Van Etten et al., 1989; Mayer and Baltimore, 1994) . This SH3-mediated inhibition might be due either to interaction with inhibitory proteins or to intramolecular folding. Since we have used recombinant c-Abl the involvement of inhibitory proteins in our system is unlikely. We show that in vitro and in nuclear extracts c-Abl is physically associated with RFX1. The c-Abl-RFX1 interaction was localized to the N-terminal PxxP motif of RFX1 and the SH3 domain of c-Abl. These domains are also required for c-Abl kinase activation by RFX1, suggesting that c-Abl-RFX1 interaction is a prerequisite step for this process. However, as this interaction leads mainly to c-Abl auto-phosphorylation with a low level of RFX1 phosphorylation, both in vitro and in vivo, we do not think that we are evidencing here a simple enzyme-substrate interaction.
The activation of the c-Abl kinase domain by RFX1 might be explained, at least in part, by the sequestration of the SH3 inhibitory role. In the Ablfamily, regulation of the tyrosine kinase activity by a cis-SH3 domain seems to be a general theme. Both cSrc and Hck protein tyrosine kinases were shown to be intra-molecularly inhibited mainly by the SH3 domain (Xu et al., 1997; Sicheri et al., 1997) . Moreover, binding of the Nef PxxP motif to the SH3 domain, in vitro, relieves its inhibition and fully activates the kinase . The intra-molecular interaction and inhibition of the tyrosine kinase by the SH3 domain is indirect and mediated through a 14 amino-acids linker region between the SH2 and kinase domains (Xu et al., 1997; Sicheri et al., 1997) . Most intriguingly, a similar linker region is found in c-Abl with about 40% identity to c-Src. This conservation may indicate that the RFX1 mediated c-Abl activation acts by sequestering the inhibitory eect of the SH3 domain on the kinase. However, the potency of c-Abl kinase activation by RFX1 is extreme and exceeds by far that of v-Abl (Figure 7a and b, compare intact bands in lanes 2 and 8). The latter, lacking the SH3 domain, is considered a constitutive and very ecient protein tyrosine kinase. Thus, kinase super-activation by RFX1 cannot be attributed only to sequestration of the c-Abl SH3 domain, but also to some additional cAbl allosteric changes. Recently, two proteins of the same family, Abl Interactor protein 1 and 2 (Abi1 and 2), were found to modulate c-Abl activity by binding to both the SH3 domain and the proline rich region at the N-and the Cterminal regions of c-Abl, respectively (Dai and Pendergast, 1995; Shi et al., 1995) . Notably, the RFX1 proline rich sequence is highly similar to that of Abi1. Interestingly, Abi1 and 2, in addition to binding c-Abl, also have a putative DNA binding domain, suggesting that, like RFX1, these proteins may attract c-Abl to DNA. Therefore, it is possible that c-Abl is associated with dierent DNA cis-elements through proteinprotein interactions with the cognate DNA-binding protein. However, RFX1 and Abi display opposite eects on c-Abl kinase activity, in that the former activates, while the latter inhibits it. Thus, the c-Abl SH3 domain may exert both positive and negative eects on its catalytic domain. Moreover in Drosophila positive regulation of Abl protein, namely recognition of its substrate Ena, was mediated by its SH3 domain (Gertler et al., 1995) . This dual role of the SH3 domain may oer a mechanism that is highly sensitive to signals and extremely selective for substrates.
Our results also uncover a mechanism for recruitment of a tyrosine kinase domain to a DNA-cis element with its concomitant activation. Obviously, the most immediate aim is to de®ne the role of the kinase domain in the transcription machinery. In contrast to the positive role of EP in viral enhancers, the EP-DNA element, as a multimer and an isolation, does not activate transcription (Ostapchuk et al., 1989; Dikstein et al., 1990; Reinhold et al., 1995; Labrie et al., 1995; Safrany and Perry, 1995; Katan et al., 1997) . RFX1 itself contains several independent functional domains. An activation and a repression domains which are mutually neutralized, producing a nearly inactive transcription factor (Katan et al., 1997) . Curiously, RFX1 also contains a modulator region at its extreme N-terminus which overlaps with the c-Abl binding site (amino acids 1 ± 77). This region is important for the level of RFX1 expression and DNA binding activity. Whether c-Abl is responsible for this modulator activity is yet an open question.
This context-dependent activity of EP-site raises the possibility that the associated c-Abl may modify either other enhancer binding proteins or components of the general transcription machinery. Two enhancer elements, GB and E, were shown to cooperate with EP (Ghazal et al., 1988; Dikstein et al., 1990; Garcia et al., 1993) . Extremely intriguing is the E element, which binds the ATF2 and Cyclic-AMP responsive element binding protein (CREB) families Maguire et al., 1991) . One member of this family, CREB, was found to be transcriptionally potentiated by c-Abl through physical interaction (Birchenall et al., 1995) . Modulation of the HBV enhancer binding activators by the nearby associated c-Abl is an interesting possibility to be investigated, however, as the available c-Abl-7/7 cells are not of liver origin, at the moment this study is not trivial. Alternatively, it is possible that recruited c-Abl modulates transcription by phosphorylation of the POLII C-terminal domain (CTD, Baskaran et al., 1993) .
Among several cellular binding sites of the EP nucleo-protein complex, one is located in the ®rst intron of the c-myc gene (MIE) and another in the promoter of the PCNA gene (Zajac et al., 1988; Labrie et al., 1995) both of which are expressed in a cell cycle dependent manner. The role of EP in regulating these genes is not fully understood. A hint for a possible role of MIE in myc gene expression has been noticed from the study of the myc gene sequence in dierent Burkitt's lymphomas. It has been found that in these tumor cells, whose myc gene expression is deregulated, MIE is frequently mutated (Zajac et al., 1988) . It is therefore assumed that MIE is involved in the silencing of c-myc transcription, which is correlated with cellular differentiation and cell growth arrest. Interestingly, both cAbl and RFX1 are implicated in these processes, c-Abl was shown to inhibit cell growth (Sawyers et al., 1994) and Sak1 + , a yeast homolog of RFX1, was shown to be involved in sex dierentiation and exit from the mitotic cell cycle to G 0 (Wu and McLeod, 1995) . Thus, the EP protein complex may represent a novel transcription component that regulates cell growth through the tyrosine kinase activity of c-Abl.
Materials and methods
Plasmid constructions and cell transfection pSG5-HARFX1, in which the expression of HA-tagged RFX1 is driven by SV2, was constructed by altering the bases at position 73 to +3, relative to the initiation start site of RFX1 open reading frame, to form an NdeI site. Then, an EcoRI ± NdeI HA epitope was ligated to EcoRI digested pSG5 together with an RFX1 fragment (NdeI ± EcoRI). PSG5-HARFX1D(1 ± 77) was generated by NdeI ± SacI double digest and ligation together with an in-frame NdeI ± SacI linker. pSG5-HARFX1D(77 ± 588) was generated by SacI digest. For bacterial expression of RFX1, RFX1D(1 ± 77) and RFX1D(77 ± 588) DNA fragments were excised from their corresponding pSG5 plasmids by NheI ± EcoRI and inserted in frame into pRSET-B (Qiagen).
For preparation of recombinant c-Abl-SH3 domain, for far western ®lter binding assay, human c-Abl 1b cDNA c-Abl kinase potentiation and RFX1 DNA-binding R Agami and Y Shaul (Shtivelman et al., 1986) was digested with HinDIII ± HinCII (amino acids 15 ± 147 and inserted in-frame to pRSET-C. A protein kinase phosphorylation site (PKS) was created by annealing of the two oligoes 5'-CTAGCCTCCGGA-GAGCTTCTCTTG-3' and 5'-CTAGCAAGAGAAGCTCT-CCGGAGAGG-3' and insertion into the NheI site, forming pRSET-PKS-c-Abl-SH3 to produce rPKS-abl-SH3. Vectors for production of recombinant c-Abl were constructed by inserting either an intact or truncated (amino acids 15 ± 667) human c-Abl 1b cDNA into the HinDIII and PVuII sites of pRSET-C, respectively. In each case the structure of the constracts was veri®ed by enzymatic digestion and sequencing.
For transfection, SK-Hepl cells were cultured in Dulbeco modi®ed Eagle minimal essential medium containing 100 U of penicillin per ml and 100 mg strepomycin per ml supplemented with 10% fetal calf serum. Sixteen to 20 h before transfection, 2610 5 cells were plated per 60 mm dish. Cells were transfected as described (Honigwachs et al., 1989) .
Preparation of recombinant proteins
To generate soluble recombinant proteins, the plasmids pRSET-RFX1, pRSET-RFX1D(1 ± 77), pRSET c-Abl and pRSET-c-Abl(15 ± 667) were transformed into BL21-Lys S bacteria cells, plated on LB-Amp plates and a single colony was chosen for an overnight starter culture. M9ZB+0.4% glucose, half a liter, was seeded with 1/30 of the starter and expression was induced at an optimal density OD595=0.5 by adding IPTG to a ®nal concentration of 0.5 mM. After 60 min, cells were harvested, washed with cold PBS, resuspended in lysis buer (25 mM HEPES (7.5), 5 mM MgCl 2 ,10% glycerol, 10 mM b-mercaptoethanol and 200 mM NaCl) and lysed by ®ve times 30 s-sonications. The lysis buer contained 1 mM freshly-made phenylmethylsulfonyl¯uoride, 10 mM benzamidine hydrocloride, and 10 mg/ml each of 1,10 phenantroline, aprotenin and leupeptin protease inhibitors. After removal of insoluble inclusion bodies by centrifugation at 15 000 r.p.m. for 20 min at 48C, soluble histidine-tagged or Glutathion-Stransferase (GST)-tagged proteins were puri®ed from lysates using either NiNTA resin (Qiagen) or glutathion agarose beads (Sigma) and eluted with lysis buer containing either 200 mM Imidazole or 5 mM of glutathion, respectively. For puri®cation of GST-tagged proteins, 1 mM DTT and 1 mM EDTA were added to the solutions. Puri®ed proteins were dialyzed against buer D (20 mM HEPES-KOH (pH 7.9), 50 mM KCl, 1 mM DTT, 1 mM EDTA, 10% glycerol and protease inhibitors). Proteins were puri®ed to homogeneity and each step of the extraction and puri®cation was followed by Coomassie staining, c-Abl was puri®ed as a 140 kDa with a 80 kDa degraduated polypeptide, c-Abl(15 ± 667) was puri®ed as a 90 kDa with a degraduation product of 65 kDa polypeptide. As all were His-tagged at the N-terminus they must be truncated at the C-terminus.
For ®lter binding assays, total bacterial proteins containing either RFX1 (rRFX1) or rRFX1D(1 ± 77) were used. These proteins were expressed as described above, only they were induced with 0.5 mM IPTG for 3 h. The resulting insoluble fractions were collected and washed three times with PBS and resuspended in 1 ml sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS ± PAGE) sample buer. Typically, 20 ± 60 ml was used for ®lter binding assay to achieve *1 mg of the induced full length proteins on the gel. For the Western analysis, 100 ng of recombinant proteins was used.
Immunoprecipitation and immunoblotting
For coimmunoprecipitation of RFX1 with c-Abl, HeLa cells nuclear extracts were generated as described (Dignam et al., 1983a, and b) . Immunoprecipitation was done with polyclonal anti-Abl 543 antibodies that were raised against amino acids 631-981 of human c-Abl fused to bGal (Ana® et al., 1992; Dikstein et al., 1992) and boosted by the same c-Abl 350 amino acids tagged with a histidine epitope. Immunoblotting was performed by standard procedure (Towbin et al., 1979) and ®lters were reacted with the secondary antibodies, either sheep antimouse or protein A, conjugated to horseradish peroxidase (Pharmingen). Immunocomplexes were detected using the ECL detection system (Amersham). For immunoblot detection of RFX1 and c-Abl, we used the polyclonal anti-RFX1, a generous gift of B Mach (Reith et al., 1990) , the c-Abl speci®c monoclonal 8E9 antibody (Pharmingen, San Diego) and as control, the monoclonal 245 anti-Rb antibody (Pharmingen, San Diego). For coimmunoprecipitation of c-Abl with RFX1, three 100 mm dishes of SKHep1 cells that were transfected with HA-tagged RFX1 expression plasmids, were lysed on ice for 10 min in 200 ml of 50 mM Tris : HCl (8.0), 1 mM EDTA, 250 mM NaCl, 1% Triton X-100 and 1 mM DTT. All solutions also contained protease and phosphatase inhibitors. Lysates were cleared by centrifugation at 15 0006g for 10 min at 48C. Immunoprecipitation was done in NET buer (50 mM Tris (8.0), 1 mM EDTA and 150 mM NaCl and 10 mg/ml BSA) on ice for 2 h using 10 mg of monoclonal anti-HA 12CA5 (Pharmingen, San Diego) or 20 mg of rabbit anti mouse (RaM) antibody (Pharmingen, San Diego). Immune complexes were brought down by protein A/G Sepharose beads (Santa-Cruz) and washed six times with ice cold NET buer.
Filter binding assay
For preparation of 32 P labeled abl-SH3, to be used as a probe for ®lter binding assays, puri®ed soluble rPKS-abl-SH3 (0.5 mg) was phosphorylated with 8 mg/ml protein kinase (PK, Sigma) in 50 ml, containing 20 mM Tris : HCl (7.4) 1 mM DTT, 100 mM NaCl, 12 mM MgCl 2 and 50 mCi [g-32 P]ATP (5000 mCi/mmol, Amersham) for 15 min at 378C. Kinase reaction was stopped with 1 ml stop solution (10 mM NaPi, 10 mM NaPPi and 1 mg/ml BSA). Free [g-32 P]ATP was removed by employing the Ni-NTA anity resin (Qiagen). Bound proteins were eluted with 100 ml of stop solution containing 200 mM Imidazole (Sigma) and were used as a probe. Nitrocellulose ®lters, containing total bacterial proteins together with the recombinant protein of interest, were blocked in TBST (50 mM Tris (pH 8.0), 150 mM NaCl 0.1% Tween-20, 0.1% Gelatin, 2% non-fat milk powder) containing also 0.5 mg, non-labeled, 10 min boiled rPKS-abl-SH3 protein.
After 2 h incubation at 48C with constant shaking, 32 p rPKS-abl-SH3 was added at a speci®c radioactivity of 10 6 c.p.m. per ml, and incubation was continued at 48C for additional 2 h. Subsequently, the ®lters were washed ®ve times with cold TBST, each for 5 min, and exposed to autoradiogram for 10 h.
In vitro and in vivo phosphorylation assays
For in vitro reactions puri®ed soluble recombinant proteins were incubated in kinase buer containing 20 mM HEPES-KOH (pH 7.5), 20 mM MnCl 2 and 1 mM DTT, at 48C for 30 min in 15 ± 18 ml reaction. Phosphorylation was initiated by addition of 20 ± 50 mCi [g-32 P]ATP (5000 mCi/mmol, Amersham) and incubation at 308C for 30 min (Kharbanda et al., 1995) . Phosphorylation rate, under these conditions, was linear for more than 1 h. Reactions were stopped by addition of 1 ml stop solution (see ®lter binding assay) and free [g-32 P]ATP was removed by either employing the NI-NTA (Qiagen) column for the His-tagged proteins or the glutathion agarose beads (Sigma) for GST-fused proteins. For the kinase-immunoprecipitation assay, reaction mixtures were boiled for 2 min after the kinase reaction and then subjected to immunoprecipitation with either the polyclonal anti-RFX1 or the monoclonal 8E9 anti-Abl antibodies, as described above. In vivo phosphorylation and extract preparation was carried out as described (Dikstein et al., 1996) .
Phosphoamino acid analysis
Proteins after separation on SDS ± PAGE were blotted to PVDF membrane (Bio-Rad). Then, the labeled bands were excised from the membrane and incubated for 2 h in 6 M HCl at 1108C. Subsequently, phosphoaminoacid analysis was carried out as described (Boyle, 1991) . Phosphoamino acid standards were visualized by 0.25% Ninhydrin staining in acetone.
